Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study
Background: Real-world evidence plays a pivotal role in validating the efficacy of biologic drugs beyond the controlled environment of randomized trials. This study aimed to evaluate the effectiveness of tildrakizumab in treating moderate-to-severe psoriasis within a real-world setting over a 52-wee...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioExcel Publishing Ltd
2024-03-01
|
| Edice: | Drugs in Context |
| Témata: | |
| On-line přístup: | https://www.drugsincontext.com/tildrakizumab-for-the-treatment-of-moderate-to-severe-psoriasis-a-52-week-real-world-portuguese-multicentric-study/ |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|